Type 2 diabetes—Therapy with dipeptidyl peptidase IV inhibitors
- 1 August 2005
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
- Vol. 1751 (1) , 33-44
- https://doi.org/10.1016/j.bbapap.2005.05.010
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- GLP-1 Receptor Agonists and DPP-4 Inhibitors in the Treatment of Type 2 DiabetesHormone and Metabolic Research, 2004
- Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?Expert Opinion on Investigational Drugs, 2004
- Inhibition of Food Intake in Obese Subjects by Peptide YY3–36New England Journal of Medicine, 2003
- The structure and function of human dipeptidyl peptidase IV, possessing a unique eight-bladed β-propeller foldBiochemical and Biophysical Research Communications, 2003
- Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspectiveBiochemical and Biophysical Research Communications, 2002
- Metformin Effects on Dipeptidylpeptidase IV Degradation of Glucagon-like Peptide-1Biochemical and Biophysical Research Communications, 2002
- CD26: a surface protease involved in T-cell activationImmunology Today, 1994
- Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serumEuropean Journal of Biochemistry, 1993
- The role of proline in the proteolytic regulation of biologically active peptidesBiopolymers, 1987
- Involvement of Plasma Membrane Dipeptidyl Peptidase IV in Fibronectin-Mediated Adhesion of Cells on CollagenBiological Chemistry Hoppe-Seyler, 1985